MedPath

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Registration Number
NCT00023699
Lead Sponsor
Gynecologic Oncology Group
Brief Summary

RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal cancer.

PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.

Detailed Description

OBJECTIVES:

* Determine the antitumor cytostatic activity of gefitinib, in terms of 6-month progression-free survival, in patients with persistent or recurrent ovarian epithelial or primary peritoneal carcinoma.

* Determine the nature and degree of toxicity in patients treated with this drug.

* Determine the partial and complete response rates in patients treated with this drug.

* Determine the duration of progression-free and overall survival in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral gefitinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 22-60 patients will be accrued for this study within 1-2 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (53)

University of Alabama at Birmingham Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

Jonsson Comprehensive Cancer Center, UCLA

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Community Hospital of Los Gatos

πŸ‡ΊπŸ‡Έ

Los Gatos, California, United States

Chao Family Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Orange, California, United States

University of Colorado Cancer Center

πŸ‡ΊπŸ‡Έ

Denver, Colorado, United States

Walter Reed Army Medical Center

πŸ‡ΊπŸ‡Έ

Washington, District of Columbia, United States

H. Lee Moffitt Cancer Center and Research Institute

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

Rush-Presbyterian-St. Luke's Medical Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

University of Chicago Cancer Research Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Indiana University Cancer Center

πŸ‡ΊπŸ‡Έ

Indianapolis, Indiana, United States

Scroll for more (43 remaining)
University of Alabama at Birmingham Comprehensive Cancer Center
πŸ‡ΊπŸ‡ΈBirmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.